Compounds > amifostine anhydrous

amifostine anhydrous and tamoxifen

amifostine anhydrous has been researched along with tamoxifen in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Glover, DJ1
Inano, H; Kobayashi, H; Onoda, M; Suzuki, K; Wakabayashi, K1
Blasiak, J; Blasinska-Morawiec, M; Kolacinska, A; Morawiec, Z; Morawiec-Bajda, A; Wozniak, K; Zadrozny, M1

Reviews

1 review(s) available for amifostine anhydrous and tamoxifen

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for amifostine anhydrous and tamoxifen

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
New approaches to the chemotherapy of melanoma.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5

    Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine

1991
Prevention of radiation-induced mammary tumours in rats by combined use of WR-2721 and tamoxifen.
    International journal of radiation biology, 2000, Volume: 76, Issue:8

    Topics: Amifostine; Animals; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Female; Mammary Neoplasms, Experimental; Neoplasms, Radiation-Induced; Radiation-Protective Agents; Rats; Rats, Wistar; Tamoxifen

2000
The DNA-damaging potential of tamoxifen in breast cancer and normal cells.
    Archives of toxicology, 2007, Volume: 81, Issue:7

    Topics: Adult; Amifostine; Ascorbic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Comet Assay; DNA; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; DNA-Formamidopyrimidine Glycosylase; Dose-Response Relationship, Drug; Endodeoxyribonucleases; Estrogen Receptor Modulators; Female; Free Radical Scavengers; Genistein; Humans; Hydrogen-Ion Concentration; Kinetics; Lymphocytes; Male; Mutagens; Oxidative Stress; Reactive Oxygen Species; Tamoxifen

2007